Precipio, Inc. (PRPO) Stock

Precipio, Inc. is a healthcare solutions provider based in New Haven, Connecticut, specializing in diagnostic products, reagents, and services primarily within the United States. The company focuses on offering advanced diagnostic blood cancer testing services, leveraging its proprietary technologies and products. One of its key innovations is IV-Cell, a specialized cell culture media that facilitates the simultaneous culturing of four hematopoietic cell lineages, enhancing efficiency and accuracy in diagnostic procedures.

In addition to IV-Cell, Precipio provides HemeScreen, a comprehensive suite of genetic diagnostic panels designed to assess various hematologic malignancies. The company also utilizes ICE-COLD PCR, a proprietary and patented specimen technology that significantly enhances the sensitivity of molecular-based tests, thereby improving diagnostic accuracy and reliability. Moreover, Precipio offers COVID-19 antibody tests, contributing to the global efforts in combating the pandemic.

Precipio, Inc. collaborates closely with leading academic institutions specializing in cancer research, diagnostics, and treatment. These partnerships underscore its commitment to advancing diagnostic capabilities and developing innovative solutions that meet the evolving needs of healthcare providers and patients alike in the fight against cancer and infectious diseases.